Dear Dr. Tezel:

The Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) has completed its review of your premarket approval application (PMA) for the Natrelle® 410 Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implants. This device is indicated for women for the following uses (procedures):

- **Breast Augmentation** for women at least 22 years old. Breast augmentation includes primary breast augmentation to increase the breast size, as well as revision surgery to correct or improve the result of a primary breast augmentation surgery.

- **Breast Reconstruction.** Breast reconstruction includes primary reconstruction to replace breast tissue that has been removed due to cancer or trauma or that has failed to develop properly due to a severe breast abnormality. Breast reconstruction also includes revision surgery to correct or improve the result of a primary breast reconstruction surgery.

We are pleased to inform you that the PMA is approved. You may begin commercial distribution of the device in accordance with the conditions of approval described below.

The sale and distribution of this device are restricted to prescription use in accordance with 21 CFR 801.109 and under section 515(d)(1)(B)(ii) of the Federal Food, Drug, and Cosmetic Act (the act). The device is further restricted under section 515(d)(1)(B)(ii) of the act insofar as the labeling must specify the specific training or experience practitioners need in order to use the device. FDA has determined that these restrictions on sale and distribution are necessary to
provide reasonable assurance of the safety and effectiveness of the device. Your device is therefore a restricted device subject to the requirements in sections 502(q) and (r) of the act, in addition to the many other FDA requirements governing the manufacture, distribution, and marketing of devices. More specifically, completion of your physician training program is required as a condition of access to your product. FDA will, however, allow a 90-day transition period for all current Core and Continued Access Studies investigators, after which these physicians must also have completed the training program in order to have access to the Allergan product.

Expiration dating for this device has been established and approved at 5 years.

Continued approval of this PMA is contingent upon the submission of periodic reports, required under 21 CFR 814.84, at intervals of one year (unless otherwise specified) from the date of approval of the original PMA. Two copies of this report, identified as "Annual Report" (please use this title even if the specified interval is more frequent than one year) and bearing the applicable PMA reference number, should be submitted to the address below. The Annual Report should indicate the beginning and ending date of the period covered by the report and should include the information required by 21 CFR 814.84.

In addition to the above, and in order to provide continued reasonable assurance of the safety and effectiveness of the device, the Annual Report must include, separately for each model number (if applicable), the number of devices sold and distributed during the reporting period, including those distributed to distributors. The distribution data will serve as a denominator and provide necessary context for FDA to ascertain the frequency and prevalence of adverse events, as FDA evaluates the continued safety and effectiveness of the device.

In addition to the conditions outlined above, you must conduct the following post-approval studies that will evaluate the long-term safety and effectiveness of your approved device.

1. **PMA Core Study**

At the time of approval, all patients in the PMA Core study have completed their 10 year follow-up, i.e. the last patient was enrolled to the study on February 28, 2002. Therefore, you must submit a final study report for the Premarket Core Study within 90 days of your receipt of this letter. Please submit the final report as a PAS study report to the PMA and in addition please submit a supplement to the IDE referencing the final report is being submitted for P040046.

2. **Natrelle 410 Full and Moderate height/projection Breast Implant Continued Access Study (Natrelle 410 CAS)**
Per Natrelle 410 Full and Moderate height/projection Breast Implant Continued Access Study protocol version dated August 17, 2012 (e-mail), the Natrelle 410 CAS will consist of the continued follow-up, for 5-years post-implantation, of approximately 3,500 subjects who were enrolled before the date of approval in the 410 Continued Access and 410 Continued Access Revision/Reconstruction Expansion clinical studies. All safety and effectiveness endpoints evaluated premarket will continue to be studied through 5-years of follow-up. Descriptive statistics will be provided. Additional analyses will be performed as per protocol version dated August 17, 2012. You are also required to conduct Device Explant Analyses for all devices retrieved from women enrolled in the Natrelle 410 CAS as outlined in the protocol version dated June 8, 2012.

On an annual basis and until the completion of 5 year follow-up, you must submit, a PAS progress report to FDA that includes: patient compliance, a summary of findings for all study endpoints, and results of the device explant analyses for devices explanted within this study.


Per Natrelle 410 US Post-approval Study protocol version dated August 16, 2012 (e-mail), this study is a newly enrolled cohort study in the US. The purpose of this study is to evaluate the long-term clinical performance of Natrelle 410 Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implants under general conditions of use in the postmarket environment. The study will enroll 2,287 women receiving Natrelle 410 Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implants and 300 women receiving Natrelle Saline implants as the comparison group. Study subjects will be followed annually for 10 years. Data will be collected on the following safety endpoints: connective tissue diseases (CTDs), rheumatologic and neurologic signs and symptoms, cancer (lung and breast, including the potential of breast implant interference with mammography and delay of breast cancer detection), suicide/attempted suicide, local complications (including infection, rupture; including rupture rate following mammography), reoperation and implant removal, reproductive complications in women who attempt to have children, lactation complications, and congenital deformities. The effectiveness will be assessed by participants’ responses to questions addressing their satisfaction with the breast implants and psychosocial well-being.

Data are to be collected via annual patient questionnaires. For the patients who receive Natrelle 410 Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implants, there will also be physician evaluations at years 1, 5, and 10. Descriptive statistics will be provided for the studied endpoints. In addition, the association between the studied endpoints and the approved device
will be assessed as per protocol version dated August 16, 2012. You are also required to conduct Device Explant Analyses for all devices retrieved from women enrolled in the Natrelle 410 US-PAS per protocol version dated June 8, 2012. You must report results of these explant analyses in the post-approval study Annual Report.

You also agree to participate as a stakeholder in developing the National Breast Implants Registry and to contribute data from your Natrelle 410 US Post-Approval Study to the Registry upon its implementation. Please be advised that because the establishment of the National Breast Implants Registry is currently in progress, this condition of approval will be labeled as “Study Pending” upon further notification from the FDA. Under this agreement, you must submit interim reports every 6 months that include: (1) activities that you undertake for the development of the National Breast Implant Registry; (2) US sales data for the Natrelle 410 breast implants; and (3) US implant data for the Natrelle 410 breast implants.

Otherwise, your reporting requirements for the Natrelle 410 US-PAS are as follows:
On a quarterly basis, you must submit a report to FDA that includes: (1) the number enrolled by subjects receiving studied device versus enrolled in comparison group; (2) the number enrolled by indication (primary augmentation, revision-augmentation, primary reconstruction, revision-reconstruction) for subjects receiving studied device; (3) the number enrolled by race/ethnicity; (4) the enrollment rates versus the stated goals; (5) the reason why eligible patients were not enrolled into the study; and (6) the follow-up rates versus the stated goals. FDA will inform you when quarterly reports are no longer necessary.

In addition, every 6 months for the first 2 years and then annually, thereafter, you are to submit a progress report that includes: (1) the status of patient enrollment as it compares to the stated goals; (2) the status of the race/ethnicity distribution as it compares to the stated goals; (3) detailed patient and device accounting; (4) the reasons why eligible patients were not enrolled into the study; (5) the follow-up rates versus the stated goals; and (6) a summary of findings for all study endpoints.

You must update your patient and physician labeling to reflect 5 and 10-year Natrelle 410 US-PAS study findings, as soon as these data are available, as well as any other time point deemed necessary by FDA, if significantly new information from this study becomes available.

4. **Allergan Silicone Breast Implants and Case-control Studies**

In order to evaluate the rare endpoints, we approve your proposal to conduct case-controlled studies using data that is already collected in countries where the device has been on the market for years. Per Allergan Silicone Breast Implants and Case-control Study protocols version dated August 3, 2012 (e-mail), the purpose of the Allergan Silicone Breast Implants and Case-control Studies is to evaluate the association between Natrelle 410 Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implants and five rare disease outcomes (rare connective tissue
diseases, rare neurological diseases, brain cancer, cervical/vulvar cancer and lymphoma). These studies will be conducted in the United Kingdom and will enroll a total of 7,500 cases and 4,000 controls. For each of the five rare disease outcomes, 1,500 cases will be enrolled and compared to the controls on the history of the implantation of Natrelle silicone gel-filled breast implants.

Every 6 months for the first 2 years and then annually, you must submit a report to FDA that includes: (1) the number enrolled by cases and controls; (2) the enrollment rate versus the stated goal. FDA will inform you when quarterly reports are no longer necessary. In addition, within 3 months of the completion of subject enrollment and data collection, you must submit a final Allergan Silicone Breast Implants and Case-control study report that includes the results and conclusions of the Allergan Silicone Breast Implants and Case-control studies.

5. Focus Group Study

Per the Focus Group Study protocol version dated September 7, 2012, the purpose of the Focus Group Study is to evaluate the augmentation and reconstruction patient labeling. This will involve an independent group obtaining responses from patients on the format and content of the approved labeling. Upon completion of the focus group study, you must submit a Final Report of the Focus Group Study findings and suggested revision of patient and physician labeling based on those findings.

6. In addition to the studies listed above, you must conduct non-PAS Device Explant Analyses for all Natrelle 410 Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implants that are retrieved in the commercial setting outside the post-approval studies, as per explant analysis protocol version dated June 8, 2012. On an annual basis, you must report the results of these Device Explant Analyses in the PMA Annual Reports.

Please be advised that the Post-Approval Study Reports should be submitted separately for each study. Two copies for each study, identified as "PMA Post-Approval Study Report" and bearing the applicable PMA reference number, should be submitted to the address below. For more information on post-approval studies, see the FDA guidance document entitled, "Procedures for Handling Post-Approval Studies Imposed by PMA Order" (www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm070974.htm#2).

Be advised that the failure to conduct any such study in compliance with the good clinical laboratory practices in 21 CFR part 58 (if a non-clinical study subject to part 58) or the institutional review board regulations in 21 CFR part 56 and the informed consent regulations in 21 CFR part 50 (if a clinical study involving human subjects) may be grounds for FDA withdrawal of approval of the PMA.
Before making any change affecting the safety or effectiveness of the device, you must submit a PMA supplement or an alternate submission (30-day notice) in accordance with 21 CFR 814.39. All PMA supplements and alternate submissions (30-day notice) must comply with the applicable requirements in 21 CFR 814.39. For more information, please refer to the FDA guidance document entitled, "Modifications to Devices Subject to Premarket Approval (PMA) - The PMA Supplement Decision-Making Process" (www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm089274.htm).

You are reminded that many FDA requirements govern the manufacture, distribution, and marketing of devices. For example, in accordance with the Medical Device Reporting (MDR) regulation, 21 CFR 803.50 and 21 CFR 803.52, you are required to report adverse events for this device. Manufacturers of medical devices, including in vitro diagnostic devices, are required to report to FDA no later than 30 calendar days after the day they receive or otherwise becomes aware of information, from any source, that reasonably suggests that one of their marketed devices:

1. May have caused or contributed to a death or serious injury; or

2. Has malfunctioned and such device or similar device marketed by the manufacturer would be likely to cause or contribute to a death or serious injury if the malfunction were to recur.

Additional information on MDR, including how, when, and where to report, is available at www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm.

In accordance with the recall requirements specified in 21 CFR 806.10, you are required to submit a written report to FDA of any correction or removal of this device initiated by you to: (1) reduce a risk to health posed by the device; or (2) remedy a violation of the act caused by the device which may present a risk to health, with certain exceptions specified in 21 CFR 806.10(a)(2). Additional information on recalls is available at www.fda.gov/Safety/Recalls/IndustryGuidance/default.htm.

CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading. CDRH will notify the public of its decision to approve your PMA by making available, among other information, a summary of the safety and effectiveness data upon which the approval is based. The information can be found on the FDA CDRH Internet HomePage located at www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/PMAApprovals/default.htm. Written requests for this information can also be made to the Food and Drug Administration, Dockets Management Branch, (HFA-305), 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. The written request should include the PMA number or docket number. Within 30 days from the date that this information is placed on the Internet, any
interested person may seek review of this decision by submitting a petition for review under section 515(g) of the act and requesting either a hearing or review by an independent advisory committee. FDA may, for good cause, extend this 30-day filing period.

Failure to comply with any post-approval requirement constitutes a ground for withdrawal of approval of a PMA. The introduction or delivery for introduction into interstate commerce of a device that is not in compliance with its conditions of approval is a violation of law.

You are reminded that, as soon as possible and before commercial distribution of your device, you must submit an amendment to this PMA submission with copies of all approved labeling in final printed form. Final printed labeling that is identical to the labeling approved in draft form will not routinely be reviewed by FDA staff when accompanied by a cover letter stating that the final printed labeling is identical to the labeling approved in draft form. If the final printed labeling is not identical, any changes from the final draft labeling should be highlighted and explained in the amendment.

All required documents should be submitted in 6 copies, unless otherwise specified, to the address below and should reference the above PMA number to facilitate processing.

U.S. Food and Drug Administration
Center for Devices and Radiological Health
PMA Document Mail Center – WO66-G609
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002

If you have any questions concerning this approval order, please contact Tajanay Ki at (301) 796-6970.

Sincerely yours,

Mark N. Melkerson

Mark N. Melkerson
Acting Director
Division of Surgical Devices
Office of Device Evaluation
Center for Devices and
Radiological Health